NI Technology Previews Earnings for Cavium, Flextronics, Celestica, Taiwan Semi & EZchip

Oct 27, 2010, 09:55 ET from Indie Research Advisors, LLC

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Next Inning Technology Research (, an online investment newsletter focused on semiconductor and technology stocks, has published earnings previews for Cavium (Nasdaq: CAVM), Flextronics (Nasdaq: FLEX), Celestica (NYSE: CLS), Taiwan Semiconductor Manufacturing (NYSE: TSM) and EZchip (Nasdaq: EZCH).

Editor Paul McWilliams has displayed uncanny accuracy in identifying winners and losers during this challenging and historic period for the markets. After calling the rally that started in March 2009 to the day and providing Next Inning readers with buy recommendations that in some cases returned in excess of 400%, he advised readers on May 3, 2010 that the markets were heading for a correction.  By the end of the day, the correction started.

In his June 7th Strategy Review, McWilliams advised readers we would see stocks rally in July, but that the rally would be followed by another selloff in August. As we know now, both events materialized as predicted.  On August 30th, Next Inning published McWilliams' Fall Strategy Review that outlines what he expects from the markets during the coming three months and naming five stocks he thinks will hit new highs before the close of the year.  Investors are invited to read McWilliams' market insights with no obligation during a 21-day risk-free trial.

Trial subscribers will receive the Next Inning Fall Strategy Review and highly acclaimed State of Tech reports that offer in-depth, sector-by-sector coverage of over 65 leading tech companies and specific guidance on which stocks he thinks investors should own and which should be avoided.  These reports, as well as McWilliams' regular commentary and detailed earnings previews, are available for free to trial subscribers.

In addition, subscribers will have access to McWilliams' daily commentary and actionable alerts.  To take advantage of this offer and receive these reports for free, please visit the following link:

McWilliams covers these topics and more in his recent reports:

-- The price of Cavium has nearly tripled since McWilliams advised Next Inning readers to consider it as a good strategic investment.  However, even at that, Cavium's growth came into question earlier this year and the stock has only recently been able to break back through the $30 price barrier.  What is driving Cavium's growth and what forces does McWilliams see kicking in as we move forward?  With a trailing price to earnings ratio of 33 to 1, does McWilliams think all the good news is already priced in or are there new factors that will drive the price higher?  What does he view as a fair valuation for the stock?

-- Flextronics is the largest EMS company traded on U.S. stock exchanges.  It is also leveraging a very different business model when compared to its competitors like Benchmark, Jabil and Celestica.  What makes its model unique?  Does McWilliams think Flextronics will be able to successfully scale its model to deliver higher profit margins, which is what Wall Street appears it will demand before bidding the price much higher?  Would Flextronics be a good stock to pair with either Benchmark or Celestica?  With the price of Flextronics up more than 300% since McWilliams last added shares to the Next Inning portfolio, does he think there is more room for growth or that the stock is approaching its full valuation?

-- With Benchmark already signaling we should expect weak revenue guidance from the EMS sector, what does McWilliams expect from its competitor Celestica?  What has changed at Celestica that has made it a much more attractive investment?  What other EMS company does McWilliams think makes for a good pairing with Celestica?  What makes Benchmark and Celestica stand out among their peers?

-- In one of his highly acclaimed Paradigm Papers entitled "Trends Favor Contract Semiconductor Fabricators," McWilliams carefully outlined exactly why analysts were wrong in their dismal view of sector leader TSMC.  This paper was published in December 2008, which happened to coincide with when Wall Street was predicting gloom and doom for the industry and TSMC was below $7.00.  In that paper, McWilliams suggested that Next Inning readers consider buying the stock as a long-term strategic investment.  Including nearly $1.00 in earned dividends, investors who jumped on TSMC then have enjoyed a total gain of 76%.  What does McWilliams see for TSMC going forward?  Does he think threats from its rapidly growing competitor GlobalFoundries will come into play next year?  What is he projecting for TSMC's quarterly report and what does he think represents a fair price for the stock?

-- EZchip has been a huge winner for Next Inning readers this year.  McWilliams selected it as his top pick for 2011 in two contests reserved for newsletter writers and its 100% plus gain has placed it at the top of both.  Early in the year, McWilliams set only a conservative target of $20.  Ironically, Wall Street misjudged some events at EZchip and when it was busy selling the stock off, McWilliams emphatically reassured his readers that the story was intact and boosted his target.  What is McWilliams near-term target for EZchip and what is he forecasting the company will report this week for its calendar Q3 results?  How does he view the acquisition of Wintegra by PMC Sierra impacting EZchip?  Is it a black and white story or might it be better viewed as a dual-edged sword?

Founded in September 2002, Next Inning's model portfolio has returned 285% since its inception versus 25% for the S&P 500.  

About Next Inning:

Next Inning is a subscription-based investment newsletter that provides regular coverage on more than 150 technology and semiconductor stocks.  Subscribers receive intra-day analysis, commentary and recommendations, as well as access to monthly semiconductor sales analysis, regular Special Reports, and the Next Inning model portfolio. Editor Paul McWilliams is a 30+ year semiconductor industry veteran.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926.  Interested parties may visit for additional information.  Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, Next Inning Technology Research, +1-888-278-5515

SOURCE Indie Research Advisors, LLC